JP6839199B2 - 免疫原性剤としてのストレプトコッカス・ウベリス抽出物 - Google Patents

免疫原性剤としてのストレプトコッカス・ウベリス抽出物 Download PDF

Info

Publication number
JP6839199B2
JP6839199B2 JP2018538841A JP2018538841A JP6839199B2 JP 6839199 B2 JP6839199 B2 JP 6839199B2 JP 2018538841 A JP2018538841 A JP 2018538841A JP 2018538841 A JP2018538841 A JP 2018538841A JP 6839199 B2 JP6839199 B2 JP 6839199B2
Authority
JP
Japan
Prior art keywords
vaccine
mastitis
uberis
biofilm
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018538841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504623A5 (https=
JP2019504623A (ja
Inventor
ギンベール，ロサ マリア コリャード
ギンベール，ロサ マリア コリャード
イー アマルゴス，アントニ プレナフェタ
イー アマルゴス，アントニ プレナフェタ
Original Assignee
ヒプラ シエンティフィック エセ．エレ．ウ．
ヒプラ シエンティフィック エセ．エレ．ウ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヒプラ シエンティフィック エセ．エレ．ウ．, ヒプラ シエンティフィック エセ．エレ．ウ． filed Critical ヒプラ シエンティフィック エセ．エレ．ウ．
Publication of JP2019504623A publication Critical patent/JP2019504623A/ja
Publication of JP2019504623A5 publication Critical patent/JP2019504623A5/ja
Application granted granted Critical
Publication of JP6839199B2 publication Critical patent/JP6839199B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018538841A 2016-02-15 2017-02-14 免疫原性剤としてのストレプトコッカス・ウベリス抽出物 Active JP6839199B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382060.8 2016-02-15
EP16382060 2016-02-15
PCT/EP2017/053306 WO2017140683A2 (en) 2016-02-15 2017-02-14 Streptococcus uberis extract as an immunogenic agent

Publications (3)

Publication Number Publication Date
JP2019504623A JP2019504623A (ja) 2019-02-21
JP2019504623A5 JP2019504623A5 (https=) 2020-03-26
JP6839199B2 true JP6839199B2 (ja) 2021-03-03

Family

ID=55646514

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018538841A Active JP6839199B2 (ja) 2016-02-15 2017-02-14 免疫原性剤としてのストレプトコッカス・ウベリス抽出物

Country Status (11)

Country Link
US (1) US10946085B2 (https=)
EP (1) EP3417049B1 (https=)
JP (1) JP6839199B2 (https=)
KR (1) KR102824686B1 (https=)
AU (1) AU2017220528A1 (https=)
CA (1) CA3012419A1 (https=)
ES (1) ES2960326T3 (https=)
MX (1) MX387200B (https=)
PL (1) PL3417049T3 (https=)
WO (1) WO2017140683A2 (https=)
ZA (1) ZA201805039B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023048111A1 (ja) 2021-09-21 2023-03-30 国立研究開発法人 農業・食品産業技術総合研究機構 無莢膜株を抗原として含むワクチン
EP4570265A1 (en) 2023-12-15 2025-06-18 Zaklad Badawczo-Wdrozeniowy Osrodka Salmonella "Immunolab" Sp. z o.o. Vaccine for use in preventing inflammatory conditions in cows

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60243024A (ja) * 1983-12-29 1985-12-03 Kitasato Inst:The ストレプトコツカス・サンギス感染症予防用ワクチン，診断用抗原および抗体
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2222701C (en) 1995-06-08 2012-02-07 University Of Saskatchewan Camp factor of streptococcus uberis
ES2273861T3 (es) 2000-06-12 2007-05-16 University Of Saskatchewan Inmunizacion de ganado vacuno lechero con proteina gapc frente a infecciones por streptococcus.
US20070231335A1 (en) * 2005-07-20 2007-10-04 Bruce Beutler Compositions and methods for treating Gram positive bacterial infection in a mammalian subject
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
WO2008098172A1 (en) * 2007-02-09 2008-08-14 Montana State University Enhancement of innate resistance to infection
GB0818231D0 (en) 2008-10-06 2008-11-12 Univ Nottingham Composition
BRPI1011753B8 (pt) * 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
EP2680860A4 (en) 2011-03-03 2014-08-20 Univ Alberta USE OF BACTERIAL ENDOTOXINES AND LIPOTEIC ACIDS FOR IMPROVED POSTPARTAL HEALTH AND PRODUCTIVITY OF MILK COWS AND THEIR NEWBORN
WO2012152898A1 (en) 2011-05-12 2012-11-15 Intervet International B.V. Treatment of mastitis
BR112013032675A2 (pt) * 2011-06-19 2017-08-08 Vaxine Pty Ltd composição adjuvante de vacina compreendendo partículas de inulina
KR101943171B1 (ko) 2013-09-19 2019-01-29 조에티스 서비시즈 엘엘씨 유성 아쥬반트

Also Published As

Publication number Publication date
US20190038736A1 (en) 2019-02-07
US10946085B2 (en) 2021-03-16
WO2017140683A3 (en) 2017-10-12
MX387200B (es) 2025-03-18
ES2960326T3 (es) 2024-03-04
CA3012419A1 (en) 2017-08-24
WO2017140683A2 (en) 2017-08-24
EP3417049B1 (en) 2023-08-16
JP2019504623A (ja) 2019-02-21
AU2017220528A1 (en) 2018-08-09
KR20180108619A (ko) 2018-10-04
ZA201805039B (en) 2020-05-27
BR112018015255A2 (pt) 2018-12-18
MX2018009048A (es) 2019-03-28
KR102824686B1 (ko) 2025-06-25
EP3417049A2 (en) 2018-12-26
PL3417049T3 (pl) 2024-02-19

Similar Documents

Publication Publication Date Title
Mukhopadhaya et al. Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition
KR20140029376A (ko) 미코박테리움 항원성 조성물
Angelos Moraxella
JP6839199B2 (ja) 免疫原性剤としてのストレプトコッカス・ウベリス抽出物
WO2020018429A1 (en) Rotavirus vaccine compositions and combinations and methods for making and using
KR20200076551A (ko) 마이코플라즈마 폐렴 및 흉막폐렴 예방용 백신 조성물
JP5847713B2 (ja) 豚胸膜肺炎に対するワクチン及び当該ワクチンの取得方法
JP2023517684A (ja) ストレプトコッカス・スイス血清型９、配列型１６に対する防御のためのワクチン
JP7841077B2 (ja) Ｃｌｏｓｔｒｉｄｉｕｍ ｃｈａｕｖｏｅｉワクチン及び作製方法
BR112018015255B1 (pt) Processo para a preparação de um agente imunogênico, vacina, kit de vacinação e uso de um biofilme tratado termicamente com calor
WO2022072431A1 (en) Novel pasteurella multocida strains and vaccines having hyac and nanp deletions
KR101599281B1 (ko) 폐렴연쇄상구균 유래 막소포체를 포함하는 폐렴연쇄상구균 백신 조성물
US20090269826A1 (en) Vaccine against streptococcus agalactiae infection using native or recombinant s. agalactiae glyceraldheyde-3-phosphate dehydrogenase (gapdh) as a target antigen
KR100258772B1 (ko) 돼지의 흉막폐염 백신 조성물
RU2824493C1 (ru) Штамм бактерии Actinobacillus pleuropneumoniae 8 серотипа, предназначенный для получения моно- и поливалентных иммуногенных композиций, направленных на специфическую профилактику актинобациллезной плевропневмонии свиней
US12071636B2 (en) Pasteurella multocida strains and vaccines having hyaC and nanP deletions
CN105307677A (zh) 弯曲杆菌疫苗
JP2020522471A (ja) クロストリジウム類毒素を含むワクチン
KR100421453B1 (ko) 그람음성균에 의해 유발되는 질환의 예방 백신 및 그의제조방법
SE2200142A1 (en) Chrisvacc
US20190008941A1 (en) Combined therapy and prophylaxis for genital tract infections
Nagdive Standardization of Large Scale Production of A: 1 Phage Lysate and It s Evaluation of across Serogroup and Serotype Protective Immune Response
BRPI1003753A2 (pt) composiÇÕes imunogÊnicas sinÉrgicas baseadas em antÍgenos protÉicos combinados com antÍgeno celular pertussis e toxinas inativadas
Bleakley Characteristics of Vibrio cholerae proteinases
BR102016016891B1 (pt) Fosfatase ácida recombinante rcp01850 de corynebacterium pseudotuberculosis e seu uso em vacinas de subunidade para a linfadenite caseosa

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210212

R150 Certificate of patent or registration of utility model

Ref document number: 6839199

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250